Iambic Therapeutics Inc.
IAMHealthcare|Biotechnology|US
$10.17
-1.47 (-12.63%)
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06253871 A Phase 1/1b Study of IAM1363 in HER2 Cancers | HER2 Mutation-Related Tumors, HER2 | P1 | Recruiting | 383 | Open-label | IAM1363 |